Laboratory practice
Peptide counter-ion exchange: from TFA to acetate or chloride
Most synthetic peptides arrive as trifluoroacetate salts. This page explains why, how suppliers and labs swap the counter-ion, how the swap is verified, and what it changes in the mass you weigh and in some assays.
Our overview of TFA counter-ions explains what a counter-ion is. This page covers the next question: if the counter-ion matters for your experiment, how is it changed, and how do you check that it was?
Why people exchange the counter-ion
Roux et al. (2008) put the practical reasons plainly: because of the cleavage and purification conditions, most synthesised peptides are obtained with TFA and, for cationic peptides, as trifluoroacetate salts; the trifluoroacetate interferes with infrared characterisation and may affect in vivo studies, so exchange for another counter-ion is often required. Sikora et al. (2018) cite proven toxicity of TFA towards cells and inhibition of peptide activity as the reasons exchange is purposeful. Cornish et al. (1999) reported that trifluoroacetate inhibited the proliferation of osteoblasts and chondrocytes in culture.
Two papers warn against treating the choice as simple. Pini et al. (2012) compared peptide M33 as a trifluoroacetate and as an acetate. The two forms did not differ substantially in efficacy in vitro or in vivo, but the TFA form was 5 to 30% more toxic to cells derived from normal bronchi and from cells carrying the ΔF508 CFTR variant, and produced signs of toxicity in animals immediately after administration that the acetate form did not. Sikora et al. (2018) made acetates, hydrochlorides and trifluoroacetates of five antimicrobial peptides and found a substantial difference between salts, but the pattern was not consistent across peptides: for example, the highest selectivity indices were for CAMEL hydrochloride, pexiganan acetate and temporin A trifluoroacetate. The counter-ion is a variable to specify and record, not a universal fix.
How the exchange is done
The underlying idea in every method is that the new counter-ion has to displace trifluoroacetate from the positively charged groups of the peptide, where it is tightly bound.
| Method | How it works | What the studies report |
|---|---|---|
| Repeated freeze-drying from strong acid | The peptide is dissolved in excess HCl, a stronger acid than TFA, and lyophilised, several times | Roux et al. (2008) call this the classical procedure, with the drawback that working at pH below 1 can degrade the peptide. Erckes et al. (2025) found 10 mM HCl optimal for removing TFA and saw no effect on peptide purity at any HCl concentration tested. |
| HCl-saturated organic solvent | The peptide is incubated in acetonitrile, tert-butanol or another solvent saturated with HCl, evaporated, redissolved in water and lyophilised | Sikora et al. (2018) exchanged citropin 1.1 (GLFDVIKKVASVIGGL-NH2) this way; most solvents beat the reference method of lyophilising from 0.1 M HCl, and acetonitrile and tert-butanol gave a satisfying exchange after one repetition. |
| Reversed-phase HPLC | The peptide is run with a mobile phase carrying the new acid, such as acetic acid | Roux et al. (2008), on lanreotide: partial to almost complete exchange for an ion from a weaker acid than TFA, such as acetic acid (pKa 4.5). |
| Ion-exchange resin | The peptide is passed over a resin loaded with the new counter-ion | Same report: partial to almost complete exchange for an ion from a weaker acid than TFA. |
| Deprotonation and reprotonation | The amino groups are deprotonated in basic solution, TFA removed, and the peptide reprotonated with the acid wanted | Roux et al. (2008): requires a basic solution and permits complete removal of trifluoroacetate. |
Roux et al. add that two of their three procedures offer the possibility of exchanging the initial trifluoroacetate for any other counter-ion. The pKa values explain the first row. Roux et al. give TFA a pKa of approximately 0 and HCl a pKa of −7, so HCl can displace it by mass action, while acetic acid (pKa 4.5) is weaker than TFA and needs a method that does not rely on acid strength alone, such as the resin or the HPLC route.
How to tell whether the exchange worked
An exchanged peptide needs a measurement, not just a label. The methods in the literature are:
- 19F-NMR. Trifluoroacetate carries fluorine and the peptide does not, so the 19F signal measures residual TFA directly. Roux et al. (2008) used it with 1H-NMR, and Melanson et al. (2018) used a validated 19F-qNMR method to measure the TFA counter-ion of an angiotensin II reference material at nearly 25% by mass.
- FT-IR. Roux et al. showed that ATR-IR can monitor TFA removal; Erckes et al. (2025) validated FT-IR for residual TFA.
- Ion chromatography. Kaiser and Rohrer (2004) separated trace trifluoroacetate from an excess of chloride, phosphate and other anions with a high-capacity anion-exchange column and suppressed conductivity, with method detection limits below 90 ng/mL.
- Capillary electrophoresis. Hettiarachchi and Ridge (1998) validated a method that determines acetate and TFA together in synthetic peptides in a single assay, in 2 to 8 minutes, with an internal standard and indirect UV detection.
- HPLC with an evaporative light-scattering detector. Validated alongside FT-IR and 19F-NMR by Erckes et al. (2025).
The same issue sits behind the reference-material papers: Wang et al. (2020), working on synthetic glucagon, measured water by Karl Fischer titration and TFA by ion chromatography as part of a mass balance. Counter-ion content is a measurable, reportable number; if a certificate does not give one, the salt form is an assumption.
What exchange does to the mass of peptide you weigh
Using the same ceiling model as our purity and content article (one counter-ion for each free N-terminus, lysine and arginine, with the acid masses TFA 114.02, acetic acid 60.05 and HCl 36.46 g/mol), the peptide share of the dry salt changes with the counter-ion as follows. Water is ignored, and these are estimates from sequence, not statements about any batch.
| Peptide | Peptide MW (g/mol) | Sites counted | As TFA salt | As acetate salt | As chloride (HCl) salt | More peptide per mg after TFA to acetate |
|---|---|---|---|---|---|---|
| KPV | 342.4 | 2 | 60.0% | 74.0% | 82.4% | +23.3% |
| BPC-157 | 1419.6 | 2 | 86.2% | 92.2% | 95.1% | +7.0% |
| Selank | 751.9 | 3 | 68.7% | 80.7% | 87.3% | +17.4% |
| Kisspeptin-10 | 1302.5 | 2 | 85.1% | 91.6% | 94.7% | +7.6% |
| LL-37 | 4493.3 | 12 | 76.7% | 86.2% | 91.1% | +12.4% |
| Thymosin alpha-1 | 3108.3 | 4 | 87.2% | 92.8% | 95.5% | +6.4% |
The effect is largest for short peptides with several basic sites for their mass (KPV, 23.3% more peptide per mg; Selank, 17.4%) and smallest for the larger or capped ones (thymosin alpha-1, with a blocked N-terminus, 6.4%). For BPC-157 (1419.6 g/mol, 2 sites) the model gives 86.2% peptide as the TFA salt and 92.2% as the acetate, so a given weight of the acetate form holds about 7% more peptide. If a protocol weighs powder to make a stock, changing the salt form changes the concentration by this factor, and the correction belongs in the calculation; see net peptide content and concentration.
A check against a measured value
Melanson et al. (2018) report that the TFA counter-ion in their angiotensin II candidate reference material was nearly 25% by mass. Angiotensin II (DRVYIHPF) is 1046.2 g/mol. Counting only the N-terminus and the arginine (two sites) gives 17.9% TFA by mass; adding the histidine as a third site gives 24.6%. The measured value is in line with three counter-ions per molecule, so a count that includes histidine can be closer than one restricted to lysine and arginine. That is a useful reminder that the model is a ceiling-style estimate and that measurement decides.
Acetate is volatile: a caveat that goes with the choice
Sahakijpijarn et al. (2019) studied the caveolin-1 scaffolding domain peptide CSP7 and describe acetate as a safer, more acceptable counter-ion than TFA in animal and human studies, while noting that volatile counter-ions can sublimate away during lyophilisation. They found that the pH-modifier excipient had the greatest effect on counter-ion loss, that a higher chamber pressure lowered the sublimation rate, and that loss of volatile compounds shifted the pH of the reconstituted solution and caused peptide aggregation. Counter-ion loss is therefore a process variable, not a fixed property of the salt name. An acetate lot should be characterised for its counter-ion ratio, not assumed.
A checklist for a batch that is meant to be exchanged
- The salt form is stated (TFA, acetate or chloride) and is not left to inference.
- The method of exchange is named, and residual TFA is reported with a method (19F-NMR, ion chromatography, FT-IR, CE or HPLC-ELSD).
- Counter-ion content, water and net peptide content are reported, so a concentration can be calculated; see how to read a COA.
- Purity by HPLC is reported for the exchanged material, because an exchange step can in principle alter the peptide; Erckes et al. (2025) saw no purity change with HCl, but other methods differ.
- If a cell-based or membrane assay is the intended use, the salt form is recorded with the result. Erckes et al. (2025) found permeability coefficients that depended on peptide sequence and salt form, and conclude that counter-ion quantification and specification matter in assays with synthetic peptides.
Our listings do not state a salt form for most products; the supplier lists GHRP-2 and GHRP-6 as acetates (see their compound pages), and the COA field for every product reads "Not yet provided". Ask for the salt form and counter-ion content on the batch documentation before relying on either.
Related
- TFA and other counter-ions in synthetic peptides
- Peptide purity vs peptide content: a vial mass balance
- Lyophilized peptides: what freeze-drying does and why
- Solid-phase peptide synthesis explained
- How to read a peptide COA
References
- Roux S, Zékri E, Rousseau B, et al. (2008). Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci 14:354-9. PubMed 18035848 · DOI
- Erckes V, Streuli A, Chamera Rendueles L, et al. (2025). Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides and Its Influence on Membrane Permeation. Pharmaceuticals (Basel) 18. PubMed 40872554 · DOI
- Sikora K, Neubauer D, Jaśkiewicz M, et al. (2018). Citropin 1.1 Trifluoroacetate to Chloride Counter-Ion Exchange in HCl-Saturated Organic Solutions: An Alternative Approach. Int J Pept Res Ther 24:265-270. PubMed 29720924 · DOI
- Sikora K, Jaśkiewicz M, Neubauer D, et al. (2018). Counter-ion effect on antistaphylococcal activity and cytotoxicity of selected antimicrobial peptides. Amino Acids 50:609-619. PubMed 29307075 · DOI
- Pini A, Lozzi L, Bernini A, et al. (2012). Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions. Amino Acids 43:467-73. PubMed 21984381 · DOI
- Cornish J, Callon KE, Lin CQ, et al. (1999). Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol 277:E779-83. PubMed 10567002 · DOI
- Sahakijpijarn S, Moon C, Koleng JJ, et al. (2019). Formulation Composition and Process Affect Counterion for CSP7 Peptide. Pharmaceutics 11. PubMed 31569515 · DOI
- Kaiser E, Rohrer J (2004). Determination of residual trifluoroacetate in protein purification buffers and peptide preparations by ion chromatography. J Chromatogr A 1039:113-7. PubMed 15250411 · DOI
- Hettiarachchi K, Ridge S (1998). Capillary electrophoretic determination of acetic acid and trifluoroacetic acid in synthetic peptide samples. J Chromatogr A 817:153-61. PubMed 9764489 · DOI
- Melanson JE, Thibeault MP, Stocks BB, et al. (2018). Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem 410:6719-6731. PubMed 30143839 · DOI
- Wang X, Zhang F, Li H, et al. (2020). Purity determination of synthetic glucagon using a mass balance approach. Sci Rep 10:4423. PubMed 32157163 · DOI
Frequently asked questions
Why are synthetic peptides usually TFA salts?
Trifluoroacetic acid is used to cleave peptides from the resin and to purify them by HPLC, so cationic peptides are mainly obtained as trifluoroacetate salts (Roux et al., 2008; Erckes et al., 2025).
How is TFA exchanged for another counter-ion?
Roux et al. (2008) tested RP-HPLC, ion-exchange resin and a deprotonation and reprotonation cycle on lanreotide; the classical method is repeated freeze-drying from excess HCl, which Erckes et al. (2025) optimised at 10 mM HCl, and Sikora et al. (2018) tested HCl-saturated organic solvents.
How do you know the TFA is gone?
Residual TFA is measured by 19F-NMR, FT-IR, ion chromatography, capillary electrophoresis or HPLC with an evaporative light-scattering detector; Erckes et al. (2025) validated three of these to ICH guidelines.
Is acetate always better than TFA?
Not in every assay. Pini et al. (2012) found the TFA salt of peptide M33 5 to 30% more toxic to human cells than the acetate, while Sikora et al. (2018) found the best salt differed from peptide to peptide.
Does the exchange change how much peptide I weigh?
Yes. The counter-ion is lighter after exchange to acetate or chloride, so each milligram of powder holds more peptide; the table on this page shows the ceiling-model change for six library peptides.